

# JosÃ© R Blanco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4439237/publications.pdf>

Version: 2024-02-01

114  
papers

3,004  
citations

159358

30  
h-index

205818

48  
g-index

127  
all docs

127  
docs citations

127  
times ranked

3915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. <i>Clinical Microbiology and Infection</i> , 2004, 10, 1108-1132.	2.8	328
2	Human granulocytic ehrlichiosis in Europe. <i>Clinical Microbiology and Infection</i> , 2002, 8, 763-772.	2.8	190
3	Dermacentor-borne necrosis erythema and lymphadenopathy: clinical and epidemiological features of a new tick-borne disease. <i>Clinical Microbiology and Infection</i> , 2004, 10, 327-331.	2.8	90
4	Pulmonary long-term consequences of COVID-19 infections after hospital discharge. <i>Clinical Microbiology and Infection</i> , 2021, 27, 892-896.	2.8	85
5	Cluster of Cases of Human Rickettsia felis Infection from Southern Europe (Spain) Diagnosed by PCR. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2669-2671.	1.8	78
6	Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e53992.	1.1	75
7	Rickettsia slovaca Infection: DEBONEL/TIBOLA. <i>Annals of the New York Academy of Sciences</i> , 2006, 1078, 206-214.	1.8	71
8	Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 100-107.	0.2	66
9	Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2731-2740.	1.2	65
10	Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1903-1910.	1.3	61
11	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	1.7	60
12	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1000-1006.	0.5	56
13	Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	56
14	First Report of Human Granulocytic Ehrlichiosis from Southern Europe (Spain). <i>Emerging Infectious Diseases</i> , 2000, 6, 430-432.	2.0	54
15	Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3512-3520.	1.8	46
16	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. <i>Aids</i> , 2016, 30, 37-44.	1.0	46
17	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. <i>Antiviral Therapy</i> , 2012, 17, 1-8.	0.6	43
18	Bloodstream Infections After Invasive Nonsurgical Cardiac Procedures. <i>Archives of Internal Medicine</i> , 2001, 161, 2110.	4.3	42

#	ARTICLE	IF	CITATIONS
19	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. PLoS ONE, 2006, 1, e89.	1.1	42
20	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV, 2020, 7, e565-e573.	2.1	42
21	Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosisâ€”The ESCAPE Study. Clinical Infectious Diseases, 2018, 66, 825-832.	2.9	40
22	<i>Bartonella rochalimae</i> and Other <i>Bartonella</i> spp. in Fleas, Chile. Emerging Infectious Diseases, 2009, 15, 1150-1152.	2.0	39
23	HIV infection and aging. AIDS Reviews, 2010, 12, 218-30.	0.5	38
24	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). Antiviral Research, 2011, 91, 150-153.	1.9	37
25	Rickettsiosis in Europe. Annals of the New York Academy of Sciences, 2006, 1078, 26-33.	1.8	36
26	Presence of granulocytic ehrlichia in ticks and serological evidence of human infection in La Rioja, Spain. Epidemiology and Infection, 2001, 127, 353-358.	1.0	34
27	Prevalence of Rickettsia felis in Ctenocephalides felis and Ctenocephalides canis from Uruguay. Annals of the New York Academy of Sciences, 2006, 1078, 305-308.	1.8	33
28	What Drives the Number of High-Risk Human Papillomavirus Types in the Anal Canal in HIV-Positive Men Who Have Sex With Men?. Journal of Infectious Diseases, 2013, 207, 1235-1241.	1.9	33
29	Efficacy of Cidofovir in the Treatment of Recalcitrant Molluscum Contagiosum in an AIDS Patient. Acta Dermato-Venereologica, 2000, 80, 315-316.	0.6	32
30	Prevalence of Rickettsia felis-like and Bartonella Spp. in Ctenocephalides felis and Ctenocephalides canis from La Rioja (Northern Spain). Annals of the New York Academy of Sciences, 2006, 1078, 270-274.	1.8	31
31	Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study). Clinical Infectious Diseases, 2019, 68, 120-130.	2.9	31
32	Prevalence of Spotted Fever Group Rickettsia Species Detected in Ticks in La Rioja, Spain. Annals of the New York Academy of Sciences, 2006, 1078, 320-323.	1.8	30
33	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	2.9	30
34	Gender differences for frailty in HIV-infected patients on stable antiretroviral therapy and with an undetectable viral load. PLoS ONE, 2019, 14, e0215764.	1.1	30
35	Detection of Rickettsia africae in Rhipicephalus (Boophilus) decoloratus Ticks from the Republic of Botswana, South Africa. American Journal of Tropical Medicine and Hygiene, 2007, 77, 376-377.	0.6	30
36	Septic shock in a patient infected with Rickettsia sibirica mongolitimonae, Spain. Clinical Microbiology and Infection, 2012, 18, E283-E285.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. <i>Current HIV Research</i> , 2009, 7, 612-619.	0.2	26
38	Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes. <i>Current HIV Research</i> , 2011, 9, 174-179.	0.2	23
39	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1â€“Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 21-29.	0.9	23
40	Barriers to health care services for migrants living with HIV in Spain. <i>European Journal of Public Health</i> , 2018, 28, 451-457.	0.1	23
41	DEBONEL/TIBOLA: Is <i>Rickettsia slovaca</i> the Only Etiological Agent?. <i>Annals of the New York Academy of Sciences</i> , 2005, 1063, 346-348.	1.8	21
42	COVIDâ€“19 in hospitalized HIVâ€“positive and HIVâ€“negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	1.0	21
43	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 358-362.	1.3	20
44	Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial. <i>Clinical Microbiology and Infection</i> , 2018, 24, 900-907.	2.8	20
45	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€“2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	1.1	19
46	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1693-1700.	1.3	19
47	Deprescribing of non-antiretroviral therapy in HIV-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 305-318.	0.8	19
48	Reproductive desire in women with HIV infection in Spain, associated factors and motivations: a mixed-method study. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 194.	0.9	17
49	Detection of a Non-Pathogenic Variant of <i>Anaplasma phagocytophilum</i> in <i>Ixodes ricinus</i> from La Rioja, Spain. <i>Annals of the New York Academy of Sciences</i> , 2005, 1063, 333-336.	1.8	16
50	Low Risk of Developing Human <i>Rickettsia aeschlimannii</i> Infection in the North of Spain. <i>Annals of the New York Academy of Sciences</i> , 2005, 1063, 349-351.	1.8	16
51	A Century of Rickettsiology: Emerging, Reemerging Rickettsioses, Clinical, Epidemiologic, and Molecular Diagnostic Aspects and Emerging Veterinary Rickettsioses: An Overview. <i>Annals of the New York Academy of Sciences</i> , 2006, 1078, 1-14.	1.8	16
52	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	1.9	16
53	Epidemiological and Clinical Differences among <i>Rickettsia slovaca</i> Rickettsiosis and Other Tickâ€“Borne Diseases in Spain. <i>Annals of the New York Academy of Sciences</i> , 2003, 990, 355-356.	1.8	15
54	Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM. <i>PLoS ONE</i> , 2017, 12, e0188851.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Redefining therapeutic success in HIV patients: an expert view. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2501-2518.	1.3	15
56	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 447-458.	0.3	14
57	Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. <i>HIV Medicine</i> , 2015, 16, 628-634.	1.0	14
58	Left-sided infective endocarditis in patients with liver cirrhosis. <i>Journal of Infection</i> , 2015, 71, 627-641.	1.7	14
59	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25732.	1.2	14
60	Infección por <i>Rickettsia africae</i> . Tres casos confirmados por reacción en cadena de la polimerasa. <i>Medicina Clínica</i> , 2004, 122, 786-788.	0.3	14
61	High prevalence of asymptomatic carriers of <i>Tropheryma whippelii</i> in different populations from the North of Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 340-345.	0.3	13
62	Relapsing brucellosis in a patient infected with the human immunodeficiency virus (HIV). <i>Clinical Microbiology and Infection</i> , 2003, 9, 1259-1260.	2.8	12
63	Q fever endocarditis associated with a cardiovascular implantable electronic device. <i>Clinical Microbiology and Infection</i> , 2012, 18, E482-E484.	2.8	12
64	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
65	Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. <i>Translational Research</i> , 2018, 196, 17-30.	2.2	12
66	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	1.3	12
67	Effect of Antibiotic Treatment in Patients with DEBONEL/TIBOLA. <i>Annals of the New York Academy of Sciences</i> , 2005, 1063, 257-258.	1.8	11
68	Maraviroc Ameliorates the Increased Adipose Tissue Macrophage Recruitment Induced by a High-Fat Diet in a Mouse Model of Obesity. <i>Antiviral Therapy</i> , 2017, 22, 163-168.	0.6	11
69	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.3	10
70	Impact of HIV infection on aging and immune status. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 719-731.	2.0	10
71	The challenge of aging and pharmacotherapeutic complexity in the HIV + patient. <i>Farmacia Hospitalaria</i> , 2018, 42, 120-127.	0.6	10
72	Relevant Gender Differences in Epidemiological Profile, Exposure to First Antiretroviral Regimen and Survival in the Spanish Aids Research Network Cohort. <i>Antiviral Therapy</i> , 2014, 19, 375-385.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Reproductive history before and after HIV diagnosis. <i>Medicine (United States)</i> , 2017, 96, e5991.	0.4	9
74	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.3	9
75	Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. <i>Cancers</i> , 2021, 13, 4935.	1.7	9
76	Hot Immunological Topics in HIV Infection. <i>Journal of AIDS &amp; Clinical Research</i> , 2011, 02, .	0.5	9
77	Epidemiological and Clinical Differences among DEBONEL/TIBOLA and Other Tick-Borne Diseases in Spain. <i>Annals of the New York Academy of Sciences</i> , 2003, 990, 391-392.	1.8	8
78	Evaluation of IgG Antibody Response against <i>Rickettsia conorii</i> and <i>Rickettsia slovaca</i> in Patients with DEBONEL/TIBOLA. <i>Annals of the New York Academy of Sciences</i> , 2006, 1078, 570-572.	1.8	7
79	Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipodystrophy: a pilot study. <i>Journal of the International AIDS Society</i> , 2013, 16, 18609.	1.2	7
80	DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). <i>Viruses</i> , 2022, 14, 524.	1.5	7
81	Senotherapeutics in Cancer and HIV. <i>Cells</i> , 2022, 11, 1222.	1.8	7
82	Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19544.	1.2	6
83	Epidemiological, Clinical, and Microbiological Characteristics in a Large Series of Patients Affected by Dermacentor-Borne-Necrosis-Erythema-Lymphadenopathy from a Unique Centre from Spain. <i>Pathogens</i> , 2022, 11, 528.	1.2	6
84	Q fever in Logroño: an attack scenario. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 199-203.	0.3	5
85	HCV genotype 3: a wolf in sheep's clothing. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 149-152.	2.0	5
86	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrología</i> , 2019, 39, 497-505.	0.2	5
87	Implications of maraviroc and/or rapamycin in a mouse model of fragility. <i>Aging</i> , 2020, 12, 8565-8582.	1.4	5
88	Identificación de creencias y actitudes relacionadas con la desprescripción en pacientes VIH+ de edad avanzada: Proyecto ICARD. <i>Revista Española De Quimioterapia</i> , 2021, 34, 18-27.	0.5	5
89	Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 485-493.	0.8	4
90	The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 893-897.	0.5	4

#	ARTICLE	IF	CITATIONS
91	Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study. <i>HIV Clinical Trials</i> , 2015, 16, 43-48.	2.0	4
92	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	0.6	4
93	Off-label use of maraviroc in clinical practice. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 5-8.	2.0	4
94	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study. <i>HIV Clinical Trials</i> , 2013, 14, 204-215.	2.0	3
95	The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 993-996.	2.0	3
96	IL7RA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017, 47, 719-727.	1.7	3
97	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. <i>BMC Women's Health</i> , 2018, 18, 24.	0.8	3
98	Retinol-binding protein 4 (RBP4), a potential biomarker of frailty in HIV-infected people on stable antiretroviral therapy. <i>HIV Medicine</i> , 2020, 21, 358-364.	1.0	3
99	Temporal Trends and Geographic Variability in the Prescription of Antiretroviral Treatments in People Living with HIV in Spain, 2004-2020. <i>Journal of Clinical Medicine</i> , 2022, 11, 1896.	1.0	3
100	The circadian rhythm of viruses and its implications on susceptibility to infection. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1109-1117.	2.0	3
101	Symptomatic nosocomial urinary tract infection in very elderly patients. <i>International Journal of Infectious Diseases</i> , 2006, 10, 181-183.	1.5	2
102	Digital 3-Dimensional Virtual Models in Colorectal Cancer and Its Application in Surgical Practice. <i>Surgical Innovation</i> , 2020, 27, 246-247.	0.4	2
103	Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2). <i>PLoS ONE</i> , 2020, 15, e0226724.	1.1	2
104	Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease. <i>Aging</i> , 2022, 14, 1597-1610.	1.4	2
105	Palpebral ptosis related to antiretroviral therapy: report of two new cases and review of the literature. <i>HIV and AIDS Review</i> , 2010, 9, 109-111.	0.1	1
106	Could CCR5 be a potential target against infections?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 411-414.	2.0	1
107	Quality indicators: A tool to improve efficiency. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 65-66.	0.3	1
108	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study. <i>HIV Clinical Trials</i> , 2013, 14, 204-215.	2.0	1

#	ARTICLE	IF	CITATIONS
109	Gut microbiota: so much to explore!. Expert Review of Anti-Infective Therapy, 2013, 11, 759-761.	2.0	0
110	Quality indicators: A tool to improve efficiency. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2017, 35, 65-66.	0.2	0
111	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	1.0	0
112	Executive summary of the consensus document of the HIV quality of care indicators. GESIDA updated. Enfermedades Infecciosas Y Microbiología Clínica, 2022, 40, 35-38.	0.3	0
113	Mind the polypharmacy in people living with HIV. A new challenge for the fourth 90. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2022, 40, 5-6.	0.2	0
114	Executive summary of the consensus document of the HIV quality of care indicators. GESIDA updated. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2022, 40, 35-38.	0.2	0